MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.

Eur Rev Med Pharmacol Sci

Department of Urology Surgery, The Seventh People's Hospital of Jinan, Jinan, China.

Published: March 2021

We detected some serious inaccuracies and mistakes. Therefore, the article "MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2, by M.-Z. Pan, Y.-L. Song, F. Gao, published in Eur Rev Med Pharmacol Sci 2019; 23 (20): 8795-8805-DOI: 10.26355/eurrev_201910_19274-PMID: 31696466" has been withdrawn. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/19274.

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202103_25197DOI Listing

Publication Analysis

Top Keywords

inhibits malignant
8
malignant progression
8
progression prostate
8
prostate cancer
8
cancer up-regulating
8
up-regulating ezh2
8
mir-605-3p inhibits
4
ezh2 detected
4
detected serious
4
serious inaccuracies
4

Similar Publications

Background: Metformin, the frontline treatment for diabetes, has considerable potential as an immunomodulator; however, detailed bibliometric analyses on this subject are limited.

Methods: This study extracted 640 relevant articles from the Web of Science (WOS) Core Collection and conducted visual analyses using Microsoft Excel, VOSviewer, and CiteSpace.

Results: The findings showed that research on the immunomodulatory function of metformin has grown steadily since 2017, with China and the United States being the leading contributors.

View Article and Find Full Text PDF

Objective: To investigate the role of PCBP1 in the inhibition of lung adenocarcinoma proliferation by carbon irradiation.

Methods: A549 cells were irradiated with different doses of carbon ions to observe clonal survival and detect changes in cell proliferation. Whole transcriptome sequencing and the Illumina platform were used to analyze the differentially expressed genes in A549 cells after carbon ion irradiation.

View Article and Find Full Text PDF

Bullatine A suppresses glioma cell growth by targeting SIRT6.

Heliyon

January 2025

Department of Cerebrovascular Disease, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, PR China.

Gliomas are the most common primary tumors of the nervous system, which is generally treated using adjuvant chemotherapy following surgical resection. However, patient survival time is still short, and there is currently no successful treatment for highly malignant gliomas. Bullatine A (BLA) is a diterpenoid alkaloid of the genus Aconitum which antirheumatic and anti-inflammatory pharmacological properties.

View Article and Find Full Text PDF

Unlabelled: Colorectal cancer is one of the most prevalent malignancies worldwide and a leading cause of mortality. Chemotherapy medications are often limited in use due to issues like drug resistance, P-glycoprotein efflux, and relapse of chemotherapy. In this study, we formulated a nanosuspension with curcumin and nimbin to address these limitations and assessed its anticancer potential using molecular docking and MTT assay.

View Article and Find Full Text PDF

Osteosarcoma is an aggressive bone malignancy with a high propensity for drug resistance and metastasis, leading to poor clinical outcomes. This study investigates the role of core 1 β1,3-galactosyltransferase 1 (C1GALT1) in osteosarcoma, focusing on its implications in chemoresistance. Our findings reveal that high expression of C1GALT1 is associated with advanced stages, adverse overall survival, and increased recurrence rates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!